prediction
瑞銀預期該交易將對每個基金單位分派(DPU)產生約0.5%的溫和增值效應。
A prediction by 瑞銀. Statements are as reported by the cited publishers — not verified by DecisionGateway.
該行預期,該交易將對每個基金單位分派(DPU)產生約0.5%的溫和增值效應
Discussion
Related claims
該交易將對每個基金單位分派(DPU)產生約0.5%的溫和增值效應。瑞銀 · prediction鑑於DPU增值幅度有限,瑞銀預期市場對股價的反應將基本持平。瑞銀 · prediction鑑於 DPU 增值幅度有限,瑞銀預期市場對股價的反應將基本持平。瑞銀 · prediction若以瑞銀估算的約2%的坡元融資成本計算,該交易預計可帶來約2.5%的稅前正向利差(positive carry)。瑞銀 · predictionDovish risks could cap the terminal rate below 6%.花旗 · predictionNTT DC REIT's 1HFY2027 DPU exceeds its IPO estimate by 10%.post headline · statement
More claims by 瑞銀
Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.predictionTigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.statementIf the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.predictionFrontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.statementAfter the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.statement
All claims by 瑞銀